|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US8008252B2
(en)
*
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
|
US7214660B2
(en)
*
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
ATE371680T1
(de)
|
2002-01-16 |
2007-09-15 |
Biocompatibles Uk Ltd |
Polymerkonjugate
|
|
MXPA04012496A
(es)
*
|
2002-06-21 |
2005-09-12 |
Novo Nordisk Healthcare Ag |
Glicoformos del factor vii pegilados.
|
|
GB0301014D0
(en)
*
|
2003-01-16 |
2003-02-19 |
Biocompatibles Ltd |
Conjugation reactions
|
|
WO2004075923A2
(en)
*
|
2003-02-26 |
2004-09-10 |
Nektar Therapeutics Al, Corporation |
Polymer-factor viii moiety conjugates
|
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
EP2055189A1
(en)
|
2003-04-09 |
2009-05-06 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
TR201907313T4
(tr)
*
|
2003-05-23 |
2019-06-21 |
Nektar Therapeutics |
İki PEG zinciri içeren PEG türevleri.
|
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
|
WO2005039641A2
(en)
*
|
2003-10-15 |
2005-05-06 |
The Regents Of The University Of California |
Biomacromolecule polymer conjugates
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
|
US6887952B1
(en)
*
|
2004-02-12 |
2005-05-03 |
Biosite, Inc. |
N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use
|
|
JP4805911B2
(ja)
*
|
2004-03-15 |
2011-11-02 |
ネクター セラピューティクス |
Ｈｉｖ侵入阻害剤のポリマー系組成物及び複合体
|
|
WO2005115477A2
(en)
|
2004-04-13 |
2005-12-08 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
|
WO2006010143A2
(en)
|
2004-07-13 |
2006-01-26 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
|
|
US20080176790A1
(en)
|
2004-10-29 |
2008-07-24 |
Defrees Shawn |
Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
|
|
AU2016203693B2
(en)
*
|
2004-11-12 |
2018-08-23 |
Bayer Healthcare Llc |
Site-directed modification of FVIII
|
|
AU2013203348B2
(en)
*
|
2004-11-12 |
2016-03-03 |
Bayer Healthcare Llc |
Site-directed modification of FVIII
|
|
AU2012203813B2
(en)
*
|
2004-11-12 |
2013-10-24 |
Bayer Healthcare Llc |
Site-directed modification of FVIII
|
|
KR101468345B1
(ko)
|
2004-11-12 |
2014-12-03 |
바이엘 헬스케어 엘엘씨 |
Ｆｖｉｉｉ의 부위 지향 변형
|
|
CA2591852A1
(en)
|
2004-12-27 |
2006-07-06 |
Baxter International Inc. |
Polymer-von willebrand factor-conjugates
|
|
US9029331B2
(en)
|
2005-01-10 |
2015-05-12 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
|
EP1848461A2
(en)
|
2005-02-16 |
2007-10-31 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
|
WO2006102659A2
(en)
*
|
2005-03-23 |
2006-09-28 |
Nektar Therapeutics Al, Corporation |
CONJUGATES OF AN hGH MOIETY AND A POLYMER
|
|
JP2008534559A
(ja)
*
|
2005-04-01 |
2008-08-28 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
血液凝固ｆｖｉｉｉ類似体
|
|
US20070154992A1
(en)
|
2005-04-08 |
2007-07-05 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
|
EP1885403B1
(en)
|
2005-04-12 |
2013-05-08 |
Nektar Therapeutics |
Poly(ethyleneglycol) conjugates of Lysostaphin
|
|
EP1891231A4
(en)
|
2005-05-25 |
2011-06-22 |
Novo Nordisk As |
GLYCOPEGYLATED FACTOR IX
|
|
EP1893632B1
(en)
*
|
2005-06-17 |
2015-08-12 |
Novo Nordisk Health Care AG |
Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
|
|
MX2008001706A
(es)
*
|
2005-08-04 |
2008-04-07 |
Nektar Therapeutics Al Corp |
Conjugados de una porcion g-csf y un polimero.
|
|
US20070105755A1
(en)
*
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
US20070141021A1
(en)
*
|
2005-12-19 |
2007-06-21 |
Perry Rosen |
Methylmaleimidyl polymer derivatives
|
|
US8580746B2
(en)
*
|
2006-03-30 |
2013-11-12 |
Palatin Technologies, Inc. |
Amide linkage cyclic natriuretic peptide constructs
|
|
EP2001518B1
(en)
*
|
2006-03-30 |
2013-07-10 |
Palatin Technologies, Inc. |
Cyclic natriuretic peptide constructs
|
|
US7795221B2
(en)
*
|
2006-03-30 |
2010-09-14 |
Palatin Technologies, Inc. |
Linear natriuretic peptide constructs
|
|
CA2647314A1
(en)
|
2006-03-31 |
2007-11-08 |
Baxter International Inc. |
Pegylated factor viii
|
|
US7985839B2
(en)
*
|
2006-03-31 |
2011-07-26 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
|
US7982010B2
(en)
*
|
2006-03-31 |
2011-07-19 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
|
US7645860B2
(en)
*
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
|
KR20090013816A
(ko)
*
|
2006-05-24 |
2009-02-05 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
|
|
EP2044097A4
(en)
|
2006-06-23 |
2010-10-06 |
Quintessence Biosciences Inc |
Modified ribonucleases
|
|
US8298801B2
(en)
*
|
2006-07-17 |
2012-10-30 |
Quintessence Biosciences, Inc. |
Methods and compositions for the treatment of cancer
|
|
ES2516694T3
(es)
*
|
2006-07-21 |
2014-10-31 |
Ratiopharm Gmbh |
Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
|
|
US8969532B2
(en)
*
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
|
CA2670618C
(en)
*
|
2006-12-15 |
2016-10-04 |
Baxter International Inc. |
Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
|
|
MX2009007145A
(es)
*
|
2006-12-27 |
2009-08-27 |
Nektar Therapeutics Al Corp |
Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
|
|
KR101442867B1
(ko)
*
|
2006-12-27 |
2014-09-25 |
넥타르 테라퓨틱스 |
제거될 수 있는 결합을 지니는 인자 ⅸ 부분중합체 컨주게이트
|
|
KR20100016160A
(ko)
|
2007-04-03 |
2010-02-12 |
바이오제너릭스 에이지 |
글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
|
|
WO2008154639A2
(en)
|
2007-06-12 |
2008-12-18 |
Neose Technologies, Inc. |
Improved process for the production of nucleotide sugars
|
|
US8796248B2
(en)
*
|
2007-10-05 |
2014-08-05 |
Nektar Therapeutics |
Oligomer-corticosteroid conjugates
|
|
EP2205271B1
(en)
|
2007-10-08 |
2014-05-21 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapies
|
|
CA2704234A1
(en)
*
|
2007-11-09 |
2009-05-14 |
Baxter International Inc. |
Modified recombinant factor viii and von willebrand factor and methods of use
|
|
WO2009086356A2
(en)
|
2007-12-27 |
2009-07-09 |
Baxter International Inc. |
Method and compositions for specifically detecting physiologically acceptable polymer molecules
|
|
KR101582841B1
(ko)
|
2008-02-27 |
2016-01-11 |
노보 노르디스크 에이/에스 |
콘쥬게이트된 인자 ｖｉｉｉ 분자
|
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
|
KR20100135291A
(ko)
|
2008-04-14 |
2010-12-24 |
할로자임, 아이엔씨 |
히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
|
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
|
CA2726942A1
(en)
*
|
2008-06-04 |
2009-12-10 |
Bayer Healthcare Llc |
Fviii muteins for treatment of von willebrand disease
|
|
KR101648734B1
(ko)
|
2008-06-24 |
2016-08-18 |
체에스엘 베링 게엠베하 |
연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
|
|
US8575102B2
(en)
*
|
2008-08-01 |
2013-11-05 |
Nektar Therapeutics |
Conjugates having a releasable linkage
|
|
KR101660059B1
(ko)
*
|
2008-08-22 |
2016-09-26 |
박스알타 인코퍼레이티드 |
중합체 벤질 카르보네이트-유도체
|
|
US8029782B2
(en)
|
2008-10-01 |
2011-10-04 |
Quintessence Biosciences, Inc. |
Therapeutic ribonucleases
|
|
JP4966434B2
(ja)
*
|
2008-10-15 |
2012-07-04 |
バクスター・インターナショナル・インコーポレイテッド |
結合抗体の存在下における組換え血液凝固因子のｐｅｇ化
|
|
KR101929641B1
(ko)
*
|
2008-10-17 |
2018-12-14 |
박스알타 인코퍼레이티드 |
낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자
|
|
JP5281358B2
(ja)
*
|
2008-10-27 |
2013-09-04 |
学校法人常翔学園 |
高分子、経上皮吸収促進剤、及び医薬用製剤
|
|
CA2740793A1
(en)
*
|
2008-11-03 |
2010-06-03 |
Haiyan Jiang |
Method for the treatment of hemophilia
|
|
CN103205407B
(zh)
|
2008-12-09 |
2016-03-16 |
哈洛齐梅公司 |
延长的可溶性ph20多肽及其用途
|
|
WO2010083536A1
(en)
*
|
2009-01-19 |
2010-07-22 |
Bayer Healthcare Llc |
Protein conjugate having an endopeptidase-cleavable bioprotective moiety
|
|
CA2748314C
(en)
|
2009-02-03 |
2018-10-02 |
Amunix Operating Inc. |
Extended recombinant polypeptides and compositions comprising same
|
|
EP2398822B1
(en)
*
|
2009-02-19 |
2013-01-02 |
Novo Nordisk A/S |
Modification of factor viii
|
|
EP2437786B1
(en)
|
2009-06-01 |
2016-05-18 |
Yeda Research and Development Co. Ltd. |
Prodrugs containing albumin binding probe
|
|
KR101912335B1
(ko)
|
2009-07-27 |
2018-10-26 |
리폭센 테크놀로지즈 리미티드 |
비혈액 응고 단백질의 글리코폴리시알화
|
|
US8642737B2
(en)
|
2010-07-26 |
2014-02-04 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
|
US8809501B2
(en)
|
2009-07-27 |
2014-08-19 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
|
CN106110311A
(zh)
|
2009-07-27 |
2016-11-16 |
百深公司 |
凝血蛋白缀合物
|
|
CN102497884A
(zh)
|
2009-07-27 |
2012-06-13 |
巴克斯特国际公司 |
凝血蛋白缀合物
|
|
AU2010290131C1
(en)
|
2009-08-24 |
2015-12-03 |
Amunix Operating Inc. |
Coagulation factor VII compositions and methods of making and using same
|
|
MX2012003282A
(es)
|
2009-09-17 |
2012-04-30 |
Baxter Healthcare Sa |
Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
|
|
AU2011244348B2
(en)
*
|
2010-04-20 |
2015-02-12 |
Octapharma Ag |
New stabilizing agent for pharmaceutical proteins
|
|
GB201007356D0
(en)
|
2010-04-30 |
2010-06-16 |
Leverton Licence Holdings Ltd |
Conjugated factor VIIa
|
|
GB201007357D0
(en)
*
|
2010-04-30 |
2010-06-16 |
Leverton Licence Holdings Ltd |
Conjugated factor VIII
|
|
EP2591101B1
(en)
|
2010-07-09 |
2018-11-07 |
Bioverativ Therapeutics Inc. |
Systems for factor viii processing and methods thereof
|
|
MX348420B
(es)
|
2010-07-20 |
2017-06-12 |
Halozyme Inc |
Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios.
|
|
TWI595004B
(zh)
|
2010-11-03 |
2017-08-11 |
介控生化科技公司 |
經修飾之第九因子多胜肽及其用途
|
|
HUE049352T2
(hu)
|
2010-12-22 |
2020-09-28 |
Baxalta GmbH |
Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
|
|
EP2907504B1
(en)
|
2011-02-08 |
2017-06-28 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
|
WO2012140647A2
(en)
|
2011-04-11 |
2012-10-18 |
Yeda Research And Development Co. Ltd |
Albumin binding probes and drug conjugates thereof
|
|
WO2012140650A2
(en)
|
2011-04-12 |
2012-10-18 |
Hepacore Ltd. |
Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
|
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
|
EP2720712B1
(en)
|
2011-06-17 |
2016-03-02 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
|
JP5890516B2
(ja)
|
2011-06-17 |
2016-03-22 |
ハロザイム インコーポレイテッド |
ヒアルロナン分解酵素を用いる連続的皮下インスリン注入方法
|
|
WO2013040501A1
(en)
|
2011-09-16 |
2013-03-21 |
Pharmathene, Inc. |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
|
|
AU2012328880B2
(en)
|
2011-10-24 |
2017-02-23 |
Halozyme, Inc. |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
|
EP3130347B1
(en)
|
2011-12-30 |
2019-09-18 |
Halozyme, Inc. |
Ph20 polypeptide variants, formulations and uses thereof
|
|
DK2804623T3
(da)
|
2012-01-12 |
2019-11-11 |
Bioverativ Therapeutics Inc |
Kimære faktor viii-polypeptider og anvendelser deraf
|
|
WO2013120939A1
(en)
|
2012-02-15 |
2013-08-22 |
Csl Behring Gmbh |
Von willebrand factor variants having improved factor viii binding affinity
|
|
CA2864126A1
(en)
*
|
2012-02-15 |
2013-08-22 |
Biogen Idec Ma Inc. |
Recombinant factor viii proteins
|
|
BR112014020694A2
(pt)
|
2012-02-15 |
2018-05-08 |
Amunix Operating Inc. |
proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
|
|
HRP20181187T1
(hr)
|
2012-04-04 |
2018-09-21 |
Halozyme, Inc. |
Kombinirana terapija s hijaluronidazom i taksanom koji ciljano djeluje na tumor
|
|
MY190257A
(en)
*
|
2012-04-16 |
2022-04-11 |
Cantab Biopharmaceuticals Patents Ltd |
Optimised subcutaneous therapeutic agents
|
|
EP2858659B1
(en)
|
2012-06-08 |
2019-12-25 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
|
JP2015525222A
(ja)
|
2012-06-08 |
2015-09-03 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
キメラ性凝固因子
|
|
WO2014008375A1
(en)
*
|
2012-07-05 |
2014-01-09 |
Mersana Therapeutics, Inc. |
Terminally modified polymers and conjugates thereof
|
|
HRP20200007T1
(hr)
|
2012-07-11 |
2020-03-20 |
Bioverativ Therapeutics Inc. |
Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
|
|
JP2015527350A
(ja)
*
|
2012-08-13 |
2015-09-17 |
ノヴォ ノルディスク アー／エス |
第ｖｉｉｉ因子の液体製剤
|
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
|
CA2888806A1
(en)
|
2012-10-18 |
2014-04-24 |
Biogen Idec Ma Inc. |
Methods of using a fixed dose of a clotting factor
|
|
WO2014137161A1
(ko)
*
|
2013-03-05 |
2014-09-12 |
한미약품 주식회사 |
생리활성 폴리펩타이드 결합체의 고수율 생산을 위한 개선된 제조 방법
|
|
US20160030529A1
(en)
*
|
2013-03-13 |
2016-02-04 |
Emory University |
Targeted elimination of factor viii immune cells
|
|
AR095527A1
(es)
|
2013-03-15 |
2015-10-21 |
Biogen Idec Inc |
Formulaciones de polipéptido fc-factor ix
|
|
US20200157159A1
(en)
|
2013-04-16 |
2020-05-21 |
The Board Of Regents Of The University Of Oklahoma |
Peptide compounds and compositions thereof
|
|
EP2796145B1
(en)
|
2013-04-22 |
2017-11-01 |
CSL Ltd. |
A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
|
|
SG10201710616XA
(en)
|
2013-06-28 |
2018-02-27 |
Biogen Ma Inc |
Thrombin cleavable linker with xten and its uses thereof
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
EP4108254A1
(en)
|
2013-08-14 |
2022-12-28 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
|
AU2015204646B2
(en)
|
2014-01-10 |
2020-08-27 |
Bioverativ Therapeutics Inc. |
Factor VIII chimeric proteins and uses thereof
|
|
EP3114138B1
(en)
|
2014-03-05 |
2021-11-17 |
Pfizer Inc. |
Improved muteins of clotting factor viii
|
|
CA2953593C
(en)
|
2014-07-02 |
2023-09-26 |
Csl Limited |
Modified von willebrand factor
|
|
HRP20190881T1
(hr)
|
2014-08-28 |
2019-07-12 |
Halozyme, Inc. |
Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke
|
|
ES2753391T3
(es)
|
2014-10-14 |
2020-04-08 |
Halozyme Inc |
Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
|
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
|
ES2772933T3
(es)
|
2015-03-06 |
2020-07-08 |
CSL Behring Lengnau AG |
Factor de von Willebrand modificado que tiene una semivida mejorada
|
|
WO2016188905A1
(en)
|
2015-05-22 |
2016-12-01 |
Csl Behring Recombinant Facility Ag |
Methods for preparing modified von willebrand factor
|
|
RU2017145014A
(ru)
|
2015-05-22 |
2019-06-24 |
Цсл Беринг Ленгнау Аг |
Усеченные полипептиды фактора фон виллебранда для лечения гемофилии
|
|
BR112018002150A2
(pt)
|
2015-08-03 |
2018-09-18 |
Bioverativ Therapeutics Inc |
proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
|
|
WO2017117630A1
(en)
|
2016-01-07 |
2017-07-13 |
Csl Limited |
Mutated von willebrand factor
|
|
JP6851381B6
(ja)
|
2016-01-07 |
2021-04-21 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
変異切断型フォンウィルブランド因子
|
|
KR102219859B1
(ko)
*
|
2016-06-24 |
2021-02-25 |
재단법인 목암생명과학연구소 |
재조합 단쇄 fviii 및 그 화학 접합물
|
|
JP7618383B2
(ja)
|
2016-07-22 |
2025-01-21 |
ネクター セラピューティクス |
オキシム含有リンケージを有する第ｖｉｉｉ因子部分のコンジュゲート
|
|
SG10201912360SA
(en)
|
2016-11-11 |
2020-02-27 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for treating hemophilia
|
|
CA3043397A1
(en)
|
2016-11-11 |
2018-05-17 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
|
|
IL319473A
(en)
|
2016-12-02 |
2025-05-01 |
Bioverativ Therapeutics Inc |
Methods for treating hemophilic arthritis using chimeric blood clotting factors
|
|
CN110520149A
(zh)
|
2016-12-02 |
2019-11-29 |
比奥维拉迪维治疗股份有限公司 |
诱导对凝血因子的免疫耐受性的方法
|
|
SG10202110492YA
(en)
|
2017-06-22 |
2021-11-29 |
Catalyst Biosciences Inc |
Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
|
|
US11491212B1
(en)
|
2017-09-27 |
2022-11-08 |
Catalyst Biosciences, Inc. |
Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
|
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
|
BR112020022164A2
(pt)
|
2018-05-18 |
2021-02-02 |
Bioverativ Therapeutics Inc. |
métodos de tratamento de hemofilia a
|
|
PL3823904T3
(pl)
*
|
2018-07-20 |
2026-02-23 |
Hercules Llc |
Kompozycja rozpuszczalna lub dyspergowalna w wodzie
|
|
CA3176021A1
(en)
|
2018-12-28 |
2020-07-02 |
Catalyst Biosciences, Inc. |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
WO2021154414A2
(en)
|
2020-01-29 |
2021-08-05 |
Catalyst Biosciences, Inc. |
Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
|
|
US12232007B2
(en)
*
|
2021-06-03 |
2025-02-18 |
Apple Inc. |
Systems and methods for emergency service access by reduced capability radio frequency devices
|
|
WO2025227129A2
(en)
|
2024-04-25 |
2025-10-30 |
Starrock Pharma Llc |
Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
|